ArticleCerebellum (London, England)2025
Progression of Gait Ataxia in Spinocerebellar Ataxia Type 2: Clinical Utility of Digitally Measured Gait Metrics.
Article in Cerebellum (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Monitoring the Progression of Pre-Ataxic Gait in SCA2 with Inertial Sensors Over Four Years.Cerebellum (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Identifying digital biomarkers for gait ataxia remains a key research priority in spinocerebellar ataxias (SCAs), given their potential to enhance the monitoring of disease progression. This study aimed to evaluate the progression of digitally measured gait ataxia features in symptomatic SCA2 individuals. Forty-seven clinically manifest SCA2 patients were evaluated over four years with assessments conducted at four time points whereas 39 gender-and age matched controls were studied three time in a similar time span. At each visit, participants completed a 2-minute natural walking test while wearing six body-worn inertial measurement units. Digital metrics, including stride-to-stride mean and standard deviations of gait speed; double support; stride length, stance, elevation at midswing; foot strike angle; toe off angle and toe out angle as well as the lateral step variability. Clinical scales, including the Scale for the Assessment and Rating of Ataxia (SARA) and the Inventory of Non-Ataxia Symptoms (INAS), were also assessed. All digital measures showed significant longitudinal changes over time, except for toe-out angle, lateral step variability, and gait speed variability. After controlling for gait speed, only the means of elevation at midswing, foot strike angle, and toe-off angle, as well as the variability of stride length, elevation at midswing, foot strike angle, and toe-off angle, remained unaffected. The baseline total SARA score was the strongest predictor of longitudinal changes in most gait metrics, while the SARA gait sub-score more accurately predicted changes in the mean values than the variability of these digital measures. Significant correlations were observed between longitudinal changes in SARA scores and changes in several digital measures. Our findings confirm the progressive nature of SCA2 and demonstrate that digitally measured gait metrics are sensitive biomarkers. These metrics complement traditional clinical scales, providing deeper insight into gait impairment dynamics which could improve the evaluation of therapeutic interventions.Clinical trial number: Not applicable.
Indexed as
Identifiers
41296201What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.